Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.62 |
| ▸ | MTTP | P55157 | 11/20 | 0.53 |
| ▸ | APOB | P04114 | 2/20 | 0.49 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.47 |
| ▸ | MICA | Q29983 | 1/20 | 0.47 |
| ▸ | RAET1L | Q5VY80 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Usistapide SCHEMBL29376869 | 1.00 | NPY2R (0.62) | NPY2RMTTPAPOBKLRK1MICA | |
| Usistapide SCHEMBL803531 | 1.00 | NPY2R (0.62) | NPY2RMTTPAPOBKLRK1MICA | |
| Usistapide SCHEMBL803532 | 1.00 | NPY2R (0.62) | NPY2RMTTPAPOBKLRK1MICA | |
| SCHEMBL13085248 | 0.94 | NPY2R (0.61) | NPY2RMTTPAPOB | |
| SCHEMBL13522109 | 0.94 | NPY2R (0.55) | NPY2RMTTPAPOBKLRK1MICA | |
| SCHEMBL12158027 | 0.94 | NPY2R (0.53) | NPY2RMTTPAPOBKLRK1MICA | |
| SCHEMBL13522099 | 0.93 | NPY2R (0.53) | NPY2RMTTPAPOBKLRK1MICA | |
| SCHEMBL13522119 | 0.93 | NPY2R (0.53) | NPY2RMTTPKLRK1MICARAET1L | |
| SCHEMBL12157626 | 0.93 | NPY2R (0.53) | NPY2RMTTPAPOBKLRK1MICA | |
| SCHEMBL13522185 | 0.92 | NPY2R (0.53) | NPY2RMTTPAPOBKLRK1MICA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461341-B2 | Resolution of (±)-methyl phenyl[4-[4-[[[4′(trifluoromethyl)-2-biphenylyl]carbonyl]amino]Phenyl]-1-piperidinyl]acetate | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-11 | — | — | US | claimed |
| EP-2435406-B1 | RESOLUTION OF (±)-METHYL PHENYL[4-[4-[[[4'-(TRIFLUOROMETHYL)-2-BIPHENYLYL]CARBONYL]AMINO]PHENYL]-1-PIPERIDINYL]ACETATE | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-06 | — | — | EP | claimed |
| US-20120071660-A1 | RESOLUTION OF (±)-METHYL PHENYL[4-[4-[[[4'(TRIFLUOROMETHYL)-2- BIPHENYLYL]CARBONYL]AMINO]PHENYL]-1-PIPERIDINYL]ACETATE | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-22 | — | — | US | claimed |
| JP-2011509974-A | — | — | 2011-03-31 | — | — | JP | claimed |
| WO-2010136526-A1 | RESOLUTION OF (±)-METHYL PHENYL[4-[4-[[[4'-(TRIFLUOROMETHYL)-2-BIPHENYLYL]CARBONYL]AMINO]PHENYL]-1-PIPERIDINYL]ACETATE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-02 | — | — | WO | claimed |
| US-20100286200-A1 | COMBINATION OF METFORMIN AND AN MTP INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-11 | — | — | US | claimed |
| EP-2244789-A2 | COMBINATION OF METFORMIN AND AN MTP INHIBITOR | Janssen Pharmaceutica NV (BE) | 2010-11-03 | — | — | EP | claimed |
| WO-2009090210-A2 | COMBINATION OF METFORMIN AND AN MTP INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-23 | — | — | WO | claimed |
| WO-2008090198-A1 | USE OF MTP INHIBITORS FOR INCREASING LEVELS OF SATIETY HORMONES | JANSSEN PHARMACEUTICA NV (BE) | 2008-07-31 | — | — | WO | claimed |
| EP-1806341-A2 | (+)Phenyl-(4-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperidin-1-yl)-acetic acid methyl ester as lipid lowering agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-11 | — | — | EP | claimed |
| CN-108368096-B | Crystallization procedure for obtaining canagliflozin hemihydrate crystals | 詹森药业有限公司 | 2021-12-10 | — | — | CN | disclosed |
| EP-3394051-B1 | CRYSTALLIZATION PROCEDURE FOR OBTAINING CANAGLIFLOZIN HEMIHYDRATE CRYSTALS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-22 | — | — | EP | disclosed |
| US-10323025-B2 | Crystallization procedure for obtaining canagliflozin hemihydrate crystals | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-18 | — | — | US | disclosed |
| US-20190002449-A1 | CRYSTALLIZATION PROCEDURE FOR OBTAINING CANAGLIFLOZIN HEMIHYDRATE CRYSTALS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-03 | — | — | US | disclosed |
| EP-3394051-A1 | CRYSTALLIZATION PROCEDURE FOR OBTAINING CANAGLIFLOZIN HEMIHYDRATE CRYSTALS | Janssen Pharmaceutica N.V. (BE) | 2018-10-31 | — | — | EP | disclosed |
| US-20070082888-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2007-04-12 | — | — | US | disclosed |
| US-20070082888-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2007-04-12 | — | — | US | disclosed |
| US-7169796-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-30 | — | — | US | disclosed |
| US-7169796-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-30 | — | — | US | disclosed |
| EP-1379515-B1 | LIPID LOWERING BIPHENYLCARBOXAMIDES | JANSSEN PHARMACEUTICA NV (BE) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002449-A1 | CRYSTALLIZATION PROCEDURE FOR OBTAINING CANAGLIFLOZIN HEMIHYDRATE CRYSTALS | SLC5A2, SLC5A1, SLC2A8 | NPY2R 1288/4885MTTP 393/4885APOB 189/4885 |
| US-20120071660-A1 | RESOLUTION OF (±)-METHYL PHENYL[4-[4-[[[4'(TRIFLUOROMETHYL)-2- BIPHENYLYL]CARBONYL]AMINO]PHENYL]-1-PIPERIDINYL]ACETATE | MTTP, CETP, LIPC | NPY2R 4688/4885MTTP 1/4885APOB 48/4885 |
| US-10323025-B2 | Crystallization procedure for obtaining canagliflozin hemihydrate crystals | SLC5A2, SLC5A1, SLC2A8 | NPY2R 1288/4885MTTP 393/4885APOB 189/4885 |
| US-20070082888-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | LIPC, PNLIP, APOB | NPY2R 4187/4885MTTP 9/4885APOB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.